Clinical Study

Screening Study To Identify Patients At Risk For Cardiac Amyloidosis

Posted Date: Feb 1, 2021

  • Investigator: Robert Odonnell
  • Specialties: Cardiology, Cardiovascular Disease
  • Type of Study: Observational/Survey

Transthyretin amyloidosis (ATTR) is caused by misfolded transthyretin proteins that can deposit in different organs in the body. When transthyretin fibrils deposit in the heart, an infiltrative cardiomyopathy can develop. Cardiac amyloidosis (CA) secondary to ATTR is thought to frequently go undiagnosed or misdiagnosed and is associated with increased mortality. Treatment of ATTR is a rapidly evolving area in therapeutics. Therefore, an emphasis has been placed on the development of techniques to identify patients with CA-ATTR. The purpose of this study is to use validate and then implement a bioinformatics tool to identify patients at risk for cardiac amyloidosis.


Adult Patients With Known Or Suspected Transthyretin Amyloidosis.


Amyloidosis, Infiltrative Heart Disease, Attr

For More Information:

Alex Moseley
(330) 990-5822

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.